Neurological aspects of diagnosis and treatment of motor alalia

Skoromets A.A.; Skoromets A.P.; Yurlova O.V.; Pravdukhina G.P.; Golochalova S.A.

doi:https://doi.org/10.17116/jnevro202312305174

Skoromets A.A.

Pavlov First Saint Petersburg State Medical University

ORCID: 0000-0002-5884-3110

Skoromets A.P.

Pavlov First Saint Petersburg State Medical University

ORCID: 0000-0001-7439-2690

Yurlova O.V.

Irkutsk State Medical University;
Institute for the Development of Education of the Irkutsk Region

ORCID: 0009-0002-7468-5797

Pravdukhina G.P.

Omsk State Medical University

ORCID: 0009-0009-9874-7842

Golochalova S.A.

Omsk State Medical University

ORCID: 0009-0002-1392-9807

Neurological aspects of diagnosis and treatment of motor alalia

Authors:

Skoromets A.A., Skoromets A.P., Yurlova O.V., Pravdukhina G.P., Golochalova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5): 74‑82

DOI: 10.17116/jnevro202312305174

Read: 3225 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Skoromets AA, Skoromets AP, Yurlova OV, Pravdukhina GP, Golochalova SA. Neurological aspects of diagnosis and treatment of motor alalia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):74‑82. (In Russ.)
https://doi.org/10.17116/jnevro202312305174

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To analyze the causes of violations of expressive speech in children 4—5 years old, to assess changes in neurological status in children with motor alalia without and during treatment with Cellex.

MATERIAL AND METHODS

Two groups of patients were recruited: the main group (n=30; treatment; Cellex) and the control group (n=12; without Cellex). The drug was administered in the first half of the day by 1.0 ml subcutaneously, 10 days, daily. The patient’s visit card was analyzed 4 times: before treatment, 10 days later, 1 and 2 months after the start of treatment. Statistical hypotheses were tested using the χ² and Fisher criterions, the odds ratio (OR) and the 95% confidence interval (CI) OR were determined.

RESULTS

In more than half of the cases, violations of the neurological status, the burden of the perinatal period, a decrease in cognitive tests, and a lack of fine motor skills were revealed. Left-handedness or two-handedness, overload of viewing or listening to gadgets from the age of up to a year, violations of opercular praxis were almost always noted. The effect of the drug Cellex on the «launch of speech» in children with motor alalia has been shown. It has been established that the drug is well tolerated, has no adverse side effects and has a positive effect on the «launch of speech». The progress of the dynamics of speech development, progress in play and cognitive activity was observed in all children of the main group.

CONCLUSION

The use of the drug Cellex can be effective in the treatment of children with motor alalia.

Keywords:

motor alalia in children

dysphasia with impaired expressive speech

neuroprotection

neuropeptides

Cellex

Authors:

Skoromets A.A.

Pavlov First Saint Petersburg State Medical University

ORCID: 0000-0002-5884-3110

Skoromets A.P.

Pavlov First Saint Petersburg State Medical University

ORCID: 0000-0001-7439-2690

Yurlova O.V.

Irkutsk State Medical University;
Institute for the Development of Education of the Irkutsk Region

ORCID: 0009-0002-7468-5797

Pravdukhina G.P.

Omsk State Medical University

ORCID: 0009-0009-9874-7842

Golochalova S.A.

Omsk State Medical University

ORCID: 0009-0002-1392-9807

Received:

15.02.2023

Accepted:

13.04.2023

Close metadata

References:

Badalyan LO. Detskaya nevrologiya. M.: Izd-vo «MEDpress»; 1998.
Guzeva VI, podredakciei. Rukovodstvo po detskoi nevrologii. SPb.: Izd-vo SPbGPMA; 1998.
Skvorcov IA, Ermolenko NA. Razvitie nervnoi sistemi u detei v norme i patologii. M.: Izd-vo «MEDpress-inform»; 2003.
Rukovodstvo «Logopediya». Pod red. Volkovoi L.S., Shahovskoi S.N. M. 1999.
Skoromec AA, Skoromec AP, Skoromec TA. Topicheskaya diagnostika zabolevanii nervnoisistemi. Rukovodstvo dlya vrachei. 5-e izd. Izd-vo «Politehnika»; 2004.
Belskaya GN, Pizova NV, Sokolov MA, Ismailov IA. Neuroprotection influence on course of cerebral stroke. Meditsinskiy Sovet. 2016;11:26-31. (In Russ.).
Bel’skaia GN, Chuprina SE, Vorobiev AA, et al. Cognitive disorders in stroke patients: the possibilities of pharmacological correction. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(5):33-37. (In Russ.). https://doi.org/10.17116/jnevro20161165133-37
Bel’skaia GN, Krilova LG, Sokolov MA, Izmaĭlov IA. Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy. Zhurnal Nevrologiii Psikhiatrii im. S.S. Korsakova. 2015;115(9-2):60-63. (In Russ.). https://doi.org/10.17116/jnevro20151159260-63
Belskaya GN, Sokolov MA, Izmailov IA. Neuroprotective treatment application on the 1st rehabilitayion stage of patients with ischemic stroke. Nevrologiya/Revmatologiya. 2017;3:23-26. (In Russ.).
Gaponenko IA, Bakhareva EV, Zolotareva ZM, et al. The experience of using cellex in treatment of patients with acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(4):43-47. (In Russ.). https://doi.org/10.17116/jnevro20181184143-47
Volodeeva EA, Samarina SIu, Glotova ME, et al. Effectiveness of complex rehabilitation in post-stroke patients treated with cellex. Zhurnal Nevrologiii Psikhiatrii im. S.S. Korsakova. 2020;120(8):34-41. (In Russ.). https://doi.org/10.17116/jnevro202012008134
Kovalenko AV, Safronova MN. The effect of cellex on cognitive and speech impairments in the acute stage of stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(1):40-44. (In Russ.). https://doi.org/10.17116/jnevro20151151140-44
Pizova NV, Sokolov MA, Izmaĭlov IA. Cellex in the treatment of patients with acute disturbance of cerebral blood circulation: results of a multicenter comparative open clinical trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(5):22-26. (In Russ.).
Nazarenko DA, Lutchenko EN. Experience of Neuropeptide Drug Cellex Usage in Patients with Dysphagia Due to Vertebrobasilar Stroke. Nervnyye Bolezni. 2017;1:47-51. (In Russ.).
Tanashyan MM, Domashenko MA. New possibilities of neuroprotection in the treatment of patients with acute disorders of cerebral circulation. Nervnyye Bolezni. 2016; 1:16-21. (In Russ.).
Lang TA, Sesik M. Opisanie statistiki v medicine. Rukovodstvo dlya avtorov, redaktorov I recenzentov. M.: Prakticheskaya medicina; 2011.

Falls in elderly and senile patients. Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1030

Chronic pain in elderly and senile patients. Russian Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1033

Clinical recommendations of the Ministry of Health of Russia «Gonarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/667_1

Clinical recommendations of the Ministry of Health of Russia «Coxarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/666_1

Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoart Cart. 2008;16 Suppl 3:S14-18. https://doi.org/10.1016/j.joca.2008.06.008

Du Souich P, Garcia A,Verges J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;3(8A):1451-1463. https://doi.org/10.1111/j.1582-4934.2009.00826.x

de Abajo F, Gil M, Garcia Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23:1128-1138. https://doi.org/10.1002/pds.3617

King D, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. 2020;33(6):842-847. https://doi.org/10.3122/jabfm.2020.06.200110

Bell G, Kantor E, Lampe J, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593-603. https://doi.org/10.1007/s10654-012-9714-6

Morrison L. Reduction of ischemic coronary heart disease by chondroitin sulfate. Angiology. 1971;22(3):165-174. https://doi.org/10.1177/000331977102200308

Morrison L, Enrick N. Coronary Heart Disease: Reduction of Death Rate By Chondroitin Sulfate. Angiology. 1973;24(5):269-287. https://doi.org/10.1177/000331977302400503

Nakazawa K, Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Clinical Trial. Z Alternsforsch. 1979;34(2):153-159.

Mazzucchelli R, Rodrı´guez-Martı´n S, Garcı´a-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE. 2021;16(7):e0253932. https://doi.org/10.1371/journal.pone.0253932

Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, et al. Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response. Thromb. Haemost. 2018;118(7):1329-1339. https://doi.org/10.1055/s-0038-1657753

Williams K, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561. https://doi.org/10.1161/01.atv.15.5.551

Adhikara I, Yagi K, Mayasari D, et al. Chondroitin Sulfate Nacetylgalactosaminyltransferase-2 Impacts Foam Cell Formation and Atherosclerosis by Altering Macrophage Glycosaminoglycan Chain. Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1076-1091. https://doi.org/10.1161/ATVBAHA.120.315789

Bell J, Rhind S, Di Battista A, et al. Biomarkers of glycocalyx injury are associated with delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage: a case series supporting a new hypothesis. Neurocrit Care. 2016;26(3):339-347. https://doi.org/10.1007/s12028-016-0357-4

Nuytemansa K, Ortelb T, Gomeza L, et al. Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thromb Res. 2018;161:43-51. https://doi.org/10.1016/j.thromres.2017.11.016

Ye J, Esmon C, Johnson A. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem. 1993;268(4):2373-2379.

McGee M, Wagner W. Chondroitin Sulfate Anticoagulant Activity Is Linked to Water Transfer Relevance to Proteoglycan Structure in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(10):1921-1927. https://doi.org/10.1161/01.ATV.0000090673.96120.67

Moroudas A, Weinberg P, Parker K, Winlove C. The distribution and diffusion of small ions in chondroitin sulfate, hyaluronate and some proteoglycans solutions. Biophys Chem. 1988;32(2-3):257-270. https://doi.org/10.1016/0301-4622(88)87012-1